T1	Outcomes 868 891	serious adverse events.
T2	Outcomes 928 1009	upper respiratory tract infection, headache, and back pain, all mild to moderate.
T3	Outcomes 1047 1078	mild hypersensitivity reaction.
T4	Outcomes 1120 1230	slight enlargement of a preexisting midbrain lesion. Electrocardiography and laboratory values (including CSF)
T5	Outcomes 1269 1325	microhemorrhage, vasogenic edema, or meningoencephalitis
T6	Outcomes 1428 1476	area under the plasma concentration-time profile
T7	Outcomes 1583 1606	Mean terminal half-life
T8	Outcomes 1673 1701	CSF ponezumab concentrations
T9	Outcomes 1798 1806	mean CSF